{
    "nctId": "NCT01463891",
    "briefTitle": "Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)",
    "officialTitle": "Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Inoperable or Recurrent Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 963,
    "primaryOutcomeMeasure": "Effectiveness Diagnosed by Imaging",
    "eligibilityCriteria": "Inclusion criteria :\n\n* Inoperable breast cancer\n* Recurrent breast cancer\n\nExclusion criteria :\n\n* Corresponding to contraindication of eribulin mesylate\n* Not applicable to indications of eribulin mesylate\n* Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}